Keywords
How to Cite
Abstract
Onkogen viruslar (onkoviruslar) inson saratonining global yuklamasining muhim qismini — taxminan 12–20% ini tashkil etuvchi oldini olish mumkin bo‘lgan etiologik omillar hisoblanadi. Jahon Sog‘liqni Saqlash Tashkiloti (JSST) va Xalqaro Saraton Tadqiqotlari Agentligi (IARC) ma’lumotlariga ko‘ra, 2025-yil holatiga kelib inson uchun kanserogen sifatida tasniflangan yetti ta asosiy virus mavjud: inson papilloma virusi (HPV, yuqori xavfli tiplar), gepatit B virusi (HBV), gepatit C virusi (HCV), Epstein-Barr virusi (EBV), Kaposi sarkomasi bilan bog‘liq gerpes virusi (KSHV/HHV-8), inson T-limfotrop virusi tip 1 (HTLV-1) va Merkel hujayra poliomavirusi (MCPyV).
References
1.International Agency for Research on Cancer (IARC). (2025). IARC Monographs on the Identification of Carcinogenic Hazards to Humans: Report of the Advisory Group to Recommend Priorities for the IARC Monographs during 2025–2029. Lyon: IARC. https://monographs.iarc.who.int/wp-content/uploads/2024/11/AGP_Report_2025-2029.pdf
2.Xiao Q, et al. (2025). Viral oncogenesis in cancer: from mechanisms to therapeutics. Signal Transduction and Targeted Therapy, 10: Article number (open access). https://doi.org/10.1038/s41392-025-02197-9
da Silva Torres MK, et al. (2025). The Impact of Oncogenic Viruses on Cancer Development. PMC, Article PMC12292244. https://pmc.ncbi.nlm.nih.gov/articles/PMC12292244/
3.Galati L, et al. (2024). Human Oncogenic Viruses: Characteristics and Prevention. PMC, Article PMC10974567. https://pmc.ncbi.nlm.nih.gov/articles/PMC10974567/
World Health Organization (WHO). (2023–2025). Global Cancer Observatory (GLOBOCAN) and Infection-Attributable Cancers Data. Lyon: IARC/WHO. https://gco.iarc.who.int/
de Martel C, et al. (2020, updated references in 2025 reports). Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis. The Lancet Global 4.Health (with updates in IARC 2025 reports).
Oltieva MP, et al. (2025). Epidemiology of high-risk HPV in Uzbekistan among 44000 women – genotypes, risk profiles and screening needs. PMC, Article PMC12709833. https://pmc.ncbi.nlm.nih.gov/articles/PMC12709833/
5.Sharipova IP, et al. (2024). Prevalence of high-risk human papillomavirus genotypes among women in Uzbekistan, 2021–2023. Journal of Gynecologic Oncology, 36: e7. https://doi.org/10.3802/jgo.2025.36.e7
6.ICO/IARC Information Centre on HPV and Cancer. (2023). Uzbekistan: Human Papillomavirus and Related Cancers, Fact Sheet 2023. https://hpvcentre.net/statistics/reports/UZB_FS.pdf
7.Ussai S, et al. (2025). Cervical cancer in Eastern Europe and Central Asia: the first signs of progress? The Lancet Regional Health – Europe. https://doi.org/10.1016/j.lanepe.2025.00059-7
8.Ng CS. (2025). Immunotherapy of Oncovirus-Induced Cancers: A Review on the Development and Efficacy of Targeted Vaccines. Vaccines, 13(9): 911. https://doi.org/10.3390/vaccines13090911
9.Wu P, et al. (2023, with 2025 updates). Oncogenic virus integration: Moving toward clinical applications. MedComm – Future Medicine. https://doi.org/10.1002/mef2.1393 (updated references in recent reviews).
This work is licensed under a Creative Commons Attribution 4.0 International License.
